Chemotherapy Protectant Shortage Lasting into 2018
Zinecard (dexrazoxane injection) from Pfizer Pharmaceuticals was added to the US Food and Drug Administration (FDA) drug shortages list July 14, 2017, due to a manufacturer shortages and delays.
Zinecard 250-mg single-dose vials (NDC 00013-8717-62) and Zinecard 500-mg single-dose vials (NDC 00013-8727-89) are affected.
_______________________________________________________________________
Related Content
Treatment Advances in Carcinoid Syndrome and Neuroendocrine Tumors
Prescription Drug Shortages Linked to Price Increases for Alternative Drugs
_______________________________________________________________________
The next delivery and estimated recovery for the 250-mg single-dose vial is expected during the fourth quarter of 2017. The next delivery and estimated recovery for the 500-mg Zinecard vial, however, is not expected until the third quarter of 2018.
Zinecard is used to protect the heart and other tissues in patients receiving the chemotherapy medication doxorubicin.
—Jolynn Tumolo
